LOGIN
Nabiximols improves multiple sclerosis spasticity compared to placebo over 12 weeks
October 2018
Nabiximols improves multiple sclerosis spasticity compared to placebo over 12 weeks
Study Type:Randomized Trial
OE Level Evidence:2
Journal Level of Evidence:N/A
A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex®), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis
Eur J Neurol. 2011 Sep;18(9):1122-31. doi: 10.1111/j.1468-1331.2010.03328.xDid you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
Synopsis
241 known responders to nabiximols treatment with multiple sclerosis received nabiximols (2.7 mg THC and 2.5 mg CBD per 100-uL actuation) treatment for 4 weeks, and were then randomized to receive either titrated doses of nabiximols or placebo through an oralmucosal spray over 12 weeks. The purpose of the study was to determine whether Nabiximols is associated with significantly better spasticity ...
To view the full content, login to your account,
or start your 30-day FREE Trial today.
FREE TRIAL
LOGIN
Forgot Password?
Explore some of our unlocked ACE Reports below!
Learn about our AI Driven
High Impact Search Feature
Our AI driven High Impact metric calculates the impact an article will have by considering both the publishing journal and the content of the article itself. Built using the latest advances in natural language processing, OE High Impact predicts an article’s future number of citations better than impact factor alone.
Continue
Join the Conversation
Please Login or Join to leave comments.